DEA Schedules Synthetic Kratom Opioids and Research Compound SR-17018

The U.S. Drug Enforcement Administration announced an emergency scheduling action that will temporarily place certain highly concentrated and synthetic kratom‑derived opioids into Schedule I, citing risks of dependence, respiratory depression, overdose and death. The Partnership for a Drug‑Free New Jersey endorsed the move, stating that “the opioid epidemic has taught us the devastating consequences of delaying action until dangerous substances become deeply embedded in the marketplace.”

At the same time, Students for Sensible Drug Policy and the Rights & Reason Project filed an emergency petition urging the DEA to halt the proposed Schedule I classification of SR‑17018, a NIH‑funded research compound intended to provide safer pain relief. Petitioners argue that no overdose or death has been linked to SR‑17018 and that the emergency process “criminalizes years of taxpayer‑funded scientific research.” Chemistry journalist Hamilton Morris is quoted warning that the scheduling could “fund the criminalization of the medicine they paid to create.”

Both actions illustrate ongoing debate over how the DEA balances public‑health concerns with the need to preserve scientific innovation in opioid research.